MedImmune LLC
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1987-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://medimmune.com
A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.
- Conditions
- Influenza
- Interventions
- Biological: Cold-adapted influenza vaccine trivalent (CAIV-T)Biological: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-03-02
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 240
- Registration Number
- NCT00192179
- Locations
- 🇧🇪
Catholic University Leuven, Leuven, Belgium
🇧🇪Zamenhoflaan 12, Schoten, Belgium
🇧🇪Universiteit Antwerpen, Wilrijk, Belgium
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
- Conditions
- Influenza
- Interventions
- Biological: CAIVT 10^5Biological: CAIV-T 10^7Biological: PlaceboBiological: TIV
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 173
- Registration Number
- NCT00192322
- Locations
- 🇺🇸
Division of Allergy Immunology and Infectious Disease, Pittsburgh, Pennsylvania, United States
🇺🇸Suncoast Clinical Research, Inc., New Port Richey, Florida, United States
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
- Conditions
- Influenza
- Interventions
- Biological: TIVBiological: CAIV-TBiological: Placebo
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2012-02-14
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00192309
- Locations
- 🇺🇸
David M. Radin, MD, Stamford, Connecticut, United States
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-04-03
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 44
- Registration Number
- NCT00192517
- Locations
- 🇺🇸
NorthEast Clinical Research Centers, Inc, Allentown, Pennsylvania, United States
🇺🇸South Bend Clinic, South Bend, Indiana, United States
🇺🇸Dermatology Specialists, Vista, California, United States
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: MEDI-524 (Numax-TM)
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-29
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00192465
- Locations
- 🇺🇸
SFBC International, Inc, Miami, Florida, United States
Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-12-08
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1200
- Registration Number
- NCT00192166
- Locations
- 🇸🇬
Respiratory Medicine Service, Singapore, Singapore
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
- Conditions
- Influenza
- Interventions
- Biological: FluMist
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-09-22
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 3022
- Registration Number
- NCT00192218
- Locations
- 🇺🇸
Division of General Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Division of Allergy and Infectious Diseases, University of Washington School of Medicine, Seattle, Washington, United States
Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Medi-524
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-07-28
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 217
- Registration Number
- NCT00192478
- Locations
- 🇦🇷
Hospital General de Niños "Ricardo Gutierrez", Buenos Aires, Argentina
🇨🇱Hospital Clinico Pontificia Universidad Catolica de Chile, Santiago, Chile
🇦🇷Hospital Interzonal General de Agudos "Dr. Diego Paroissien, Buenos Aires, Argentina
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold Adapted (CAIV-T) in Healthy Adults
- Conditions
- Influenza
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2021-09-13
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00192192
- Locations
- 🇺🇸
Stamford Hospital, Stamford, Connecticut, United States
Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk
- Conditions
- Severe Respiratory Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- MedImmune LLC
- Target Recruit Count
- 1500
- Registration Number
- NCT00192439
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇺🇸Lebonheur Children's Medical Center, Memphis, Tennessee, United States
🇺🇸Children's Memorial Hospital, Chicago, Illinois, United States